Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cilengitide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 20/20 | 0.77 |
| ▸ | ITGAV known ✓ | P06756 | 18/20 | 0.77 |
| ▸ | ITGB5 known ✓ | P18084 | 8/20 | 0.77 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.77 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.77 |
| ▸ | ITGA5 | P08648 | 7/20 | 0.67 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.64 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilengitide SCHEMBL26970603 | 0.99 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL34082 | 0.99 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL19534260 | 0.99 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL31098146 | 0.95 | ITGB3 (0.72) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL22193974 | 0.88 | ITGB3 (0.62) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL16884024 | 0.88 | ITGB3 (0.62) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL16883990 | 0.88 | ITGB3 (0.62) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL31294830 | 0.87 | ITGB3 (0.80) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL22193980 | 0.87 | ITGB3 (0.62) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cyclorgdfv SCHEMBL30636069 | 0.87 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4653054-A2 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | Biomed Valley Discoveries, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12433920-B2 | C. novyi for the treatment of solid tumors in non-human animals | BIOMED VALLEY DISCOVERIES, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4108248-B1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | BIOMED VALLEY DISCOVERIES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250084059-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES INC (US) | 2025-03-13 | — | — | US | disclosed |
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-13 | — | — | US | disclosed |
| US-20220306577-A1 | THIOSEMICARBAZATES AND USES THEREOF | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-09-29 | — | — | US | disclosed |
| US-11439669-B2 | C. novyi for the treatment of solid tumors in humans | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-11440881-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-09-13 | — | — | US | disclosed |
| US-11414405-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-08-16 | — | — | US | disclosed |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3730146-B1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3966223-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3966201-A1 | THIOSEMICARBAZATES AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | ITGB3 4492/4885ITGAV 4643/4885ITGB5 4712/4885 |
| US-20250084059-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | ITGB3 3814/4885ITGAV 4115/4885ITGB5 2700/4885 |
| US-11440881-B2 | Thiosemicarbazates and uses thereof | TST, ABAT, AADAC | ITGB3 1984/4885ITGAV 3639/4885ITGB5 1677/4885 |
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | ITGB3 3814/4885ITGAV 4115/4885ITGB5 2700/4885 |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | ITGB3 2159/4885ITGAV 3717/4885ITGB5 4189/4885 |
| US-11414405-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | ITGB3 4492/4885ITGAV 4643/4885ITGB5 4712/4885 |
| US-12433920-B2 | C. novyi for the treatment of solid tumors in non-human animals | MKI67, HCCS, NCF1 | ITGB3 2463/4885ITGAV 2736/4885ITGB5 3798/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | ITGB3 3275/4885ITGAV 4412/4885ITGB5 4137/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | ITGB3 1464/4885ITGAV 3394/4885ITGB5 847/4885 |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | KIT, CPA3, MKI67 | ITGB3 1701/4885ITGAV 1789/4885ITGB5 2345/4885 |
| US-11439669-B2 | C. novyi for the treatment of solid tumors in humans | HCCS, MKI67, PBK | ITGB3 2520/4885ITGAV 3642/4885ITGB5 3769/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | ITGB3 2599/4885ITGAV 4091/4885ITGB5 2510/4885 |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | ITGB3 3814/4885ITGAV 4115/4885ITGB5 2700/4885 |
| US-20220306577-A1 | THIOSEMICARBAZATES AND USES THEREOF | TST, ABAT, AADAC | ITGB3 1984/4885ITGAV 3639/4885ITGB5 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.